Compare SBSW & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBSW | BLTE |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | South Africa | United States |
| Employees | 72668 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.0B |
| IPO Year | N/A | 2021 |
| Metric | SBSW | BLTE |
|---|---|---|
| Price | $7.98 | $150.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $19.93 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 5.1M | 192.7K |
| Earning Date | 02-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $43.55 | N/A |
| Revenue Next Year | N/A | $492.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.10 | $59.12 |
| 52 Week High | $21.29 | $200.00 |
| Indicator | SBSW | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 32.79 | 51.38 |
| Support Level | N/A | $146.60 |
| Resistance Level | $9.16 | $151.41 |
| Average True Range (ATR) | 0.31 | 7.06 |
| MACD | 0.05 | -0.14 |
| Stochastic Oscillator | 8.91 | 49.82 |
Sibanye Stillwater Ltd is a South African mining and metals processing group with a diverse portfolio of operations, projects, and investments across five continents. The Group is also one of the foremost recyclers of PGM autocatalysts and has interests in mine tailings retreatment operations. It is a producer of platinum, palladium, and rhodium and is a top-tier gold producer. It also produces and refines iridium and ruthenium, nickel, chrome, copper, and cobalt. Its products are Gold, Nickel, Zinc, Chrome, PGMs, and other. Group operations are divided into two segments, South African Operations and International and recycling operations.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.